Treatment of Rheumatoid Arthritis (RA) Using Mesenchymal Stem Cells (MSC)
DOI:
https://doi.org/10.54097/td36bd55Keywords:
Rheumatoid arthritis (RA), Mesenchymal stem cells (MSCs), MSC-derived exosomes, Therapeutic strategy.Abstract
Rheumatoid arthritis (RA), as an persistent autoimmune condition, it is known for causing persistent synovitis, gradual deterioration of cartilage and bone, ultimately resulting in disability and widespread inflammation. Until now, the onset and development mechanisms of RA remain elusive, although the new technology and drugs can certainly help patients to certain degree. However, about 30% RA patients is not responsible for targeting treatment or serious side effects, such as bone marrow inhibition, organs dysfunction, and inflection due to immune inhibition. Research data showed that therapeutic mesenchymal stem cells (MSCs), is a novel therapeutic strategy with safety and effective to inhibit inflammation and promote regeneration of bone and cartilage, especially for refractory RA. Here, the author summarized the development MSC-based treatment for RA models and patients, analysis the optimistic outlook and possible difficulties for clinical applications in future.
Downloads
References
Radu AF, Bungau SG. Management of Rheumatoid Arthritis: An Overview. Cells, 2021, 10 (11): 2857.
Singh JA. Treatment Guidelines in Rheumatoid Arthritis. Rheum Dis Clin North Am, 2022, 48 (3): 679-689.
Han Y, Li X, Zhang Y, Han Y, Chang F, Ding J. Mesenchymal Stem Cells for Regenerative Medicine. Cells, 2019, 8 (8): 886.
Wang Y, Fang J, Liu B, Shao C, Shi Y. Reciprocal regulation of mesenchymal stem cells and immune responses. Cell Stem Cell, 2022, 29 (11): 1515-1530.
He T, Huang Y, Zhang C, Liu D, Cheng C, Xu W, Zhang X. Interleukin-17A-promoted MSC2 polarization related with new bone formation of ankylosing spondylitis. Oncotarget, 2017, 8 (57): 96993-97008.
Li X, Wang Y, Cai Z, Zhou Q, Li L, Fu P. Exosomes from human umbilical cord mesenchymal stem cells inhibit ROS production and cell apoptosis in human articular chondrocytes via the miR-100-5p/NOX4 axis. Cell Biol Int, 2021, 45 (10): 2096-2106.
Wang R, Hao M, Kou X, Sui B, Sanmillan ML, Zhang X, Liu D, Tian J, Yu W, Chen C, Yang R, Sun L, Liu Y, Giraudo C, Rao DA, Shen N, Shi S. Apoptotic vesicles ameliorate lupus and arthritis via phosphatidylserine-mediated modulation of T cell receptor signaling. Bioact Mater, 2022, 25: 472-484.
Álvaro-Gracia JM, Jover JA, García-Vicuña R, Carreño L, Alonso A, Marsal S, Blanco F, Martínez-Taboada VM, Taylor P, Martín-Martín C, DelaRosa O, Tagarro I, Díaz-González F. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis, 2017, 76 (1): 196-202.
Al-Dhalimy AMB, Salim HM, Shather AH, Naser IH, Hizam MM, Alshujery MK. The pathological and therapeutically role of mesenchymal stem cell (MSC)-derived exosome in degenerative diseases; Particular focus on LncRNA and microRNA. Pathol Res Pract. 2023 Aug 22; 250: 154778. Doi: 10.1016/j.prp.2023.154778. Epub ahead of print. PMID: 37683391.
Liu H, Li R, Liu T, Yang L, Yin G, Xie Q. Immunomodulatory Effects of Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Extracellular Vesicles in Rheumatoid Arthritis. Front Immunol, 2020, 11: 1912.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







